Meningococcemia

8 registered clinical trials studyying Meningococcemia.

Status	Trial	Sponsor	Phase
Completed	Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study NCT00700713	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Immunology and Safety of Menactra® in Children in Saudi Arabia NCT00539032	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine NCT00777257	Sanofi Pasteur, a Sanofi Company	Phase 4
Completed	Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents NCT00777790	Sanofi Pasteur, a Sanofi Company	Phase 2
Terminated	Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy A NCT00772629	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children NCT00771849	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Correlation Between Cytokines and the Severity of Meningococcal Disease NCT01133834	University of Sao Paulo General Hospital	—
Completed	Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjuga NCT00772070	Sanofi Pasteur, a Sanofi Company	Phase 2